The management of patients with stage IIIA non–small cell lung cancer with N2 mediastinal node involvement
RG Martins, TA D'Amico, BW Loo… - Journal of the National …, 2012 - jnccn.org
Patients with stage IIIA non–small cell lung cancer, determined based on involvement of
ipsilateral mediastinal lymph nodes, represent the most challenging management problem …
ipsilateral mediastinal lymph nodes, represent the most challenging management problem …
A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA …
N Katakami, H Tada, T Mitsudomi, S Kudoh, H Senba… - Cancer, 2012 - Wiley Online Library
BACKGROUND: This study sought to ascertain whether induction‐concurrent radiotherapy
added to chemotherapy could improve the survival of patients undergoing surgery for stage …
added to chemotherapy could improve the survival of patients undergoing surgery for stage …
Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node …
S Toyooka, K Kiura, K Shien, K Katsui… - … and thoracic surgery, 2012 - academic.oup.com
OBJECTIVES The purpose of this study was to compare the clinical outcomes of induction
chemoradiotherapy and chemotherapy and to identify the prognostic factors for non-small …
chemoradiotherapy and chemotherapy and to identify the prognostic factors for non-small …
CXCR4 and CXCL12 immunoreactivities differentiate primary non-small-cell lung cancer with or without brain metastases
S Paratore, GL Banna, M D'Arrigo, S Saita… - Cancer …, 2012 - content.iospress.com
Synchronous or metachronous brain metastases (BMs) occur in about 33% of patients
affected by non-small-cell lung cancer (NSCLC). To date, no reliable biological marker is …
affected by non-small-cell lung cancer (NSCLC). To date, no reliable biological marker is …
Hyperfractionated irradiation with 3 cycles of induction chemotherapy in stage IIIA-N2 lung cancer
Background The purpose of the present study was to improve the prognosis of patients with
stage IIIA-N2 non-small cell lung cancer (NSCLC). To achieve that goal, we performed …
stage IIIA-N2 non-small cell lung cancer (NSCLC). To achieve that goal, we performed …
Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer
JH Cho, J Kim, K Kim, YM Shim, HK Kim… - World journal of surgery, 2012 - Springer
Background The aim of the present study was to evaluate the outcomes of surgical
resection, especially bilobectomy, after chemoradiation therapy to treat stage IIIA-N2 non …
resection, especially bilobectomy, after chemoradiation therapy to treat stage IIIA-N2 non …
Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity
C Nieder - Strahlentherapie und Onkologie, 2012 - search.proquest.com
Tight budgets and increasing competition for research funding pose challenges for highly
specialized medical disciplines such as radiation oncology. Therefore, a systematic review …
specialized medical disciplines such as radiation oncology. Therefore, a systematic review …
Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice
T Okada, N Takigawa, D Kishino… - Acta medica …, 2012 - ousar.lib.okayama-u.ac.jp
Cisplatin is used to treat lung cancer; however, it is also a known carcinogen.
Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced …
Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced …
Lung adenocarcinoma
R Rosell - 2012 - Taylor & Francis
Lung adenocarcinoma | Molecular-Based Decision Making for Personalized Cancer
Management Future Medicine Logo Search This Book Anywhere Quick Search in Books Enter …
Management Future Medicine Logo Search This Book Anywhere Quick Search in Books Enter …
Challenges in the management of stage III non-small-cell lung cancers
W Wagner, A Marra - Lung Cancer Management, 2012 - Future Medicine
The treatment of locally advanced non-small-cell lung cancer at present consists of definitive
combined chemoradiotherapy using full-dose cisplatin. An irradiation dose of 60–66 Gy is …
combined chemoradiotherapy using full-dose cisplatin. An irradiation dose of 60–66 Gy is …